Mamtani R, et al. - In this post hoc subgroup analysis, researchers focused on how treatment outcomes reported in the phase 3 trials of patients with resected high-risk renal cell carcinoma treated with adjuvant sunitinib vs placebo, could be altered by age and sex in the phase 3 Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Cancer (ASSURE) trial. In 4 patient subgroups defined by sex and median age at the time of the study, they assessed adjusted hazard ratios for overall survival (OS) and disease-free survival with sunitinib or sorafenib vs placebo. They observed decreased OS in relation to sunitinib treatment in women aged >56 years, but not in women aged ≤56 years or men of any age. A statistically significant interaction by age and sex on mortality was reported for sunitinib, but not sorafenib. Overall, older women with renal cell carcinoma could experience increased mortality due to adjuvant sunitinib treatment.